Capstone Therapeutics Corp. (CAPS)
USD 2.08
(-11.49%)
USD 2.08
(-11.49%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 52.7 Million USD | -19.19% |
| 2022 | 65.21 Million USD | 7.16% |
| 2021 | 60.85 Million USD | 10.9% |
| 2020 | 54.87 Million USD | 19221.83% |
| 2019 | 284 Thousand USD | -80.77% |
| 2018 | 1.47 Million USD | -5.86% |
| 2017 | 1.56 Million USD | 32.74% |
| 2016 | 1.18 Million USD | -33.11% |
| 2015 | 1.76 Million USD | -47.8% |
| 2014 | 3.38 Million USD | -53.74% |
| 2013 | 7.31 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 53.97 Million USD | -1.82% |
| 2024 Q1 | 54.97 Million USD | 4.32% |
| 2023 Q3 | 63.32 Million USD | -3.62% |
| 2023 FY | 52.7 Million USD | -19.19% |
| 2023 Q1 | 67.17 Million USD | 3.0% |
| 2023 Q2 | 65.69 Million USD | -2.19% |
| 2023 Q4 | 52.7 Million USD | -16.77% |
| 2022 Q4 | 65.21 Million USD | -5.47% |
| 2022 Q3 | 68.98 Million USD | -5.94% |
| 2022 FY | 65.21 Million USD | 7.16% |
| 2022 Q1 | 69.18 Million USD | 7.98% |
| 2022 Q2 | 73.34 Million USD | 6.01% |
| 2021 Q3 | 66.41 Million USD | 3.42% |
| 2021 Q4 | 64.06 Million USD | -3.53% |
| 2021 Q1 | 65.9 Million USD | 20.11% |
| 2021 FY | 60.85 Million USD | 10.9% |
| 2021 Q2 | 64.21 Million USD | -2.57% |
| 2020 Q4 | 54.87 Million USD | 32.29% |
| 2020 FY | 54.87 Million USD | 19221.83% |
| 2020 Q3 | 41.47 Million USD | 0.0% |
| 2019 Q3 | 284 Thousand USD | -59.6% |
| 2019 Q4 | 284 Thousand USD | 0.0% |
| 2019 FY | 284 Thousand USD | -80.77% |
| 2019 Q1 | 1.22 Million USD | -17.33% |
| 2019 Q2 | 703 Thousand USD | -42.42% |
| 2018 FY | 1.47 Million USD | -5.86% |
| 2018 Q4 | 1.47 Million USD | -24.72% |
| 2018 Q3 | 1.96 Million USD | -18.93% |
| 2018 Q2 | 2.42 Million USD | 133.14% |
| 2018 Q1 | 1.03 Million USD | -33.84% |
| 2017 FY | 1.56 Million USD | 32.74% |
| 2017 Q1 | 882 Thousand USD | -25.38% |
| 2017 Q2 | 758 Thousand USD | -14.06% |
| 2017 Q3 | 2.03 Million USD | 168.73% |
| 2017 Q4 | 1.56 Million USD | -22.97% |
| 2016 FY | 1.18 Million USD | -33.11% |
| 2016 Q4 | 1.18 Million USD | -25.99% |
| 2016 Q3 | 1.59 Million USD | 33.08% |
| 2016 Q2 | 1.2 Million USD | -15.07% |
| 2016 Q1 | 1.41 Million USD | -20.03% |
| 2015 FY | 1.76 Million USD | -47.8% |
| 2015 Q4 | 1.76 Million USD | 14.29% |
| 2015 Q2 | 2.13 Million USD | -23.73% |
| 2015 Q1 | 2.79 Million USD | -17.34% |
| 2015 Q3 | 1.54 Million USD | -27.55% |
| 2014 Q3 | 4.09 Million USD | -22.53% |
| 2014 Q4 | 3.38 Million USD | -17.3% |
| 2014 FY | 3.38 Million USD | -53.74% |
| 2014 Q1 | 6.51 Million USD | -11.02% |
| 2014 Q2 | 5.28 Million USD | -18.86% |
| 2013 Q2 | 9.22 Million USD | -11.77% |
| 2013 FY | 7.31 Million USD | 0.0% |
| 2013 Q4 | 7.31 Million USD | -10.03% |
| 2013 Q3 | 8.13 Million USD | -11.88% |
| 2013 Q1 | 10.46 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -2281328.571% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -2591.313% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -399.346% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -9445.208% |
| Rebus Holdings, Inc. | 5000.00 USD | -1053920.0% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 59.526% |
| Qrons Inc. | 420.00 USD | -12547757.143% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -6738.566% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -88.595% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -10866.649% |
| Skye Bioscience, Inc. | 11.94 Million USD | -341.367% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -35.663% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -629.955% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -68921.924% |
| SQZ Biotechnologies Company | 107.18 Million USD | 50.833% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -3580.155% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -72726.643% |
| Mesoblast Limited | 667.9 Million USD | 92.109% |
| Marizyme, Inc. | 22.01 Million USD | -139.386% |
| Genus plc | 1.02 Billion USD | 94.878% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -3779.772% |
| Pharming Group N.V. | 462.85 Million USD | 88.614% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -1490.728% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -10460.497% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -8305.263% |
| ContraFect Corporation | 20.67 Million USD | -154.853% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -13400.407% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -13689.684% |
| IMV Inc. | 31.33 Million USD | -68.192% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -1171.122% |
| MultiCell Technologies, Inc. | 126.22 USD | -41753187.91% |
| ONE Bio Corp. | 70.08 Million USD | 24.805% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -5508.345% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 58.991% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -12107.387% |
| Q BioMed Inc. | 3.51 Million USD | -1399.097% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -49.808% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -20070.547% |
| Biomind Labs Inc. | 73.81 Thousand USD | -71292.189% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 88.192% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -3537.454% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -75.582% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -1818.957% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -7565.756% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -1924.473% |
| GB Sciences, Inc. | 103.44 Thousand USD | -50847.391% |
| Alpha Cognition Inc. | 2.45 Million USD | -2049.158% |
| HST Global, Inc. | 1526.00 USD | -3453438.663% |
| CSL Limited | 38.02 Billion USD | 99.861% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -5234.287% |
| Halberd Corporation | 10.13 Thousand USD | -520095.44% |
| Enzolytics Inc. | 361.7 Million USD | 85.43% |
| Agentix Corp. | 261.39 Thousand USD | -20061.673% |
| Resverlogix Corp. | 8.11 Million USD | -549.427% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -2706.409% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 98.84% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -10.48% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -8138.96% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -231237.518% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -488.894% |
| AVAX Technologies, Inc. | 7.37 Million USD | -614.381% |
| Zenith Capital Corp. | 7410.00 USD | -711114.575% |
| Genscript Biotech Corporation | 3.38 Billion USD | 98.444% |
| Ember Therapeutics, Inc. | 184.00 USD | -28641747.826% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -16276.637% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -20063.833% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -5579.226% |
| Kadimastem Ltd | 2.3 Million USD | -2187.29% |
| Helix BioMedix, Inc. | 3.02 Million USD | -1642.132% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -261.95% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -92205.671% |
| LadRx Corporation | 2.3 Million USD | -2183.522% |
| Cell Source, Inc. | 195.17 Thousand USD | -26902.475% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -14803.412% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -14803.412% |
| NovAccess Global Inc. | 62.24 Thousand USD | -84562.961% |
| Affymax, Inc. | 7.44 Million USD | -608.061% |
| Itoco Inc. | 1.4 Million USD | -3664.164% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -54993.72% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -49617.925% |
| Mobile Lads Corp. | 52.00 USD | -101347976.923% |
| CytoDyn Inc. | 11.13 Million USD | -373.249% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -36761.064% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -294648.322% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -13571.846% |
| SYBLEU INC | 330.46 Thousand USD | -15847.384% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -12772.049% |
| International Stem Cell Corporation | 5.39 Million USD | -877.755% |
| Bioxytran, Inc. | 137.63 Thousand USD | -38189.571% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -251.297% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -217.878% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -66610.127% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -5994.877% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -601.091% |
| Neutra Corp. | 2851.00 USD | -1848409.295% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -62.627% |
| PureTech Health plc | 693.97 Million USD | 92.406% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -552.96% |
| IXICO plc | 15.84 Million USD | -232.626% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -536.332% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 48.994% |
| CSL Limited | 38.02 Billion USD | 99.861% |
| Cellectis S.A. | 333.99 Million USD | 84.221% |